COMy 2022 | ClonoSEQ® as a tool to measure MRD negativity
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the use of clonoSEQ® as a tool for measuring measurable residual disease (MRD) in patients with multiple myeloma. Dr Ramasamy first explains the role of clonoSEQ® as a post-transplant tool for measuring MRD negativity, and further explains its application for high-risk patients. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Transcript (edited for clarity)
ClonoSEQ is a clear advance in MRD measurement technology for myeloma patients. So this involves having a sample from diagnosis and then a further sample at the time point that we want to measure MRD. We’ve been doing this for transplant patients after stem cell transplant, particularly to look at in complete remission patients, whether they are MRD negative before the start of maintenance...
ClonoSEQ is a clear advance in MRD measurement technology for myeloma patients. So this involves having a sample from diagnosis and then a further sample at the time point that we want to measure MRD. We’ve been doing this for transplant patients after stem cell transplant, particularly to look at in complete remission patients, whether they are MRD negative before the start of maintenance. In addition, for high-risk myeloma patients, the practice now has evolved to using tandem stem cell transplant and therefore, we want to identify if patients have become MRD negative following the first stem cell transplant before they go onto the second stem cell transplant. We’ll not actively made a clinical decisions based on whether the patients are MRD negative or not yet in practice, but we hope to do so as these trials that are currently running, looking at intervention changes following MRD testing becomes available.
Read more...
